These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 28222785

  • 1. TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents.
    Picchianti Diamanti A, Laganà B, Cox MC, Pilozzi E, Amodeo R, Bove M, Markovic M, Di Rosa R, Salemi S, Sorgi ML, Rosado MM, D'Amelio R.
    J Transl Med; 2017 Feb 21; 15(1):38. PubMed ID: 28222785
    [Abstract] [Full Text] [Related]

  • 2. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2009 Nov 21; 60(11):3217-24. PubMed ID: 19877042
    [Abstract] [Full Text] [Related]

  • 3. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, Benvenuto R, Fedele AL, Federico F, Ferraccioli G, Gremese E.
    Ann Rheum Dis; 2017 Jul 21; 76(7):1228-1236. PubMed ID: 28119289
    [Abstract] [Full Text] [Related]

  • 4. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J, Wu JJ, Dann FJ.
    Dermatol Ther; 2009 Jul 21; 22(1):61-73. PubMed ID: 19222518
    [Abstract] [Full Text] [Related]

  • 5. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis.
    Corrado A, Di Bello V, d'Onofrio F, Maruotti N, Cantatore FP.
    Int J Immunopathol Pharmacol; 2017 Sep 21; 30(3):302-307. PubMed ID: 28604144
    [Abstract] [Full Text] [Related]

  • 6. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, Radovits B, Veale DJ, Fitzgerald O.
    J Rheumatol; 2013 May 21; 40(5):653-62. PubMed ID: 23457381
    [Abstract] [Full Text] [Related]

  • 7. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study.
    Seitz M, Reichenbach S, Möller B, Zwahlen M, Villiger PM, Dufour JF.
    Ann Rheum Dis; 2010 Jun 21; 69(6):1148-50. PubMed ID: 19854710
    [Abstract] [Full Text] [Related]

  • 8. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Wierød A, Kalstad S, Rødevand E, Krøll F, Haugeberg G, Kvien TK.
    Ann Rheum Dis; 2017 Apr 21; 76(4):708-711. PubMed ID: 27707730
    [Abstract] [Full Text] [Related]

  • 9. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J, Inciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernández MV, Sanmartí R, Cañete JD.
    Clin Exp Rheumatol; 2017 Apr 21; 35(1):74-79. PubMed ID: 27749227
    [Abstract] [Full Text] [Related]

  • 10. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 11. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors.
    Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R.
    Autoimmun Rev; 2011 Aug 15; 10(10):617-23. PubMed ID: 21549221
    [Abstract] [Full Text] [Related]

  • 12. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M, Peragallo MS, Pietrosanti M, Di Rosa R, Picchianti Diamanti A, Salemi S, D'Amelio R.
    Intern Emerg Med; 2016 Feb 15; 11(1):31-40. PubMed ID: 26099279
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC.
    Clin Exp Immunol; 2015 Sep 15; 181(3):401-6. PubMed ID: 25766640
    [Abstract] [Full Text] [Related]

  • 14. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D, Haddad A, Hashoul S, Laor A, Bitterman H, Rosner I, Eder L, Balbir-Gurman A, Mader R, Milman U.
    J Rheumatol; 2013 Jan 15; 40(1):16-22. PubMed ID: 23070992
    [Abstract] [Full Text] [Related]

  • 15. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment.
    Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E, Guarino MD, Kroegler B, Gigliucci G, Grelli S, Perricone R.
    Clin Exp Immunol; 2014 Jul 15; 177(1):234-43. PubMed ID: 24666401
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
    Deyab G, Hokstad I, Whist JE, Smastuen MC, Agewall S, Lyberg T, Ronda N, Mikkelsen K, Hjeltnes G, Hollan I.
    Arthritis Res Ther; 2017 Oct 17; 19(1):232. PubMed ID: 29041979
    [Abstract] [Full Text] [Related]

  • 17. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 17; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 18. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS, Taylor WJ, CASPAR Study Group.
    J Rheumatol; 2008 Mar 17; 35(3):472-6. PubMed ID: 18203324
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.
    Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C, Letizia Pistoia M, Liakouli V, Ruscitti P, Ciccia F, Triolo G, Masciocchi C, Giacomelli R.
    Int J Immunopathol Pharmacol; 2016 Jun 17; 29(2):252-66. PubMed ID: 26684633
    [Abstract] [Full Text] [Related]

  • 20. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.
    Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G, CaRRDs study group.
    Arterioscler Thromb Vasc Biol; 2011 Mar 17; 31(3):705-12. PubMed ID: 21212403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.